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The expression patterns of the cannabinoid receptor type 1 (CB1R) and the cannabinoid receptor type 2 (CB2R) arewell documented
in rodents and primates. In vervet monkeys, CB1R is present in the retinal neurons (photoreceptors, horizontal cells, bipolar cells,
amacrine cells, and ganglion cells) and CB2R is exclusively found in the retinal glia (Mu¨ller cells). However, the role of these
cannabinoid receptors in normal primate retinal function remains elusive. Using full-field electroretinography in adult vervet
monkeys, we recorded changes in neural activity following the blockade of CB1R and CB2R by the intravitreal administration
of their antagonists (AM251 and AM630, resp.) in photopic and scotopic conditions. Our results show that AM251 increases the
photopic a-wave amplitude at high flash intensities, whereas AM630 increases the amplitude of both the photopic a- and b-waves.
In scotopic conditions, both blockers increased the b-wave amplitude but did not change the a-wave amplitude. These findings
suggest an important role of CB1R and CB2R in primate retinal function.
1. Introduction
The endocannabinoid system is composed of cannabinoid
receptor type 1 (CB1R), cannabinoid receptor type 2 (CB2R),
their endogenous ligands (endocannabinoids), and their syn-
thetizing and metabolizing enzymes. The physiological and
psychological effects of cannabinoids can be detected almost
everywhere in the body due to the abundance of cannabinoid
receptors. Expression patterns of CB1R and CB2R are well
documented in the retina of numerous species, including
rodents and primates [1–6]. In rodents, CB1R and CB2R are
expressed in many retinal cell types, particularly cone and
rod photoreceptors, horizontal cells, amacrine cells, bipolar
cells, and ganglion cells [1, 7]. In vervet monkeys, CB1R is
mainly found in cones of the central retina, rod spherules
with very low expression, horizontal cells, bipolar cells, and
amacrine and ganglion cells [5]. CB2R, on the other hand, is
strictly expressed in primate glialMu¨ller cells [6]. Beyond the
retina, the expression pattern of CB1R has been observed in
the dorsal lateral geniculate nucleus [8] and primary visual
cortex [9] of primates.
Most of our knowledge on the role of cannabinoids in
human vision comes from reports, anecdotes, and studies
with cannabis consumers (for review see [10]). Besides the
well-known “red eye” effect (vasodilation) of marijuana and
reduction of intraocular pressure (IOP) [11–13], the func-
tional effects of endocannabinoids on the visual system are
not yet well defined [14]. Nevertheless, the administration of
cannabinoids produces some known alterations in the human
visual system. Indeed, case studies suggested the existence of
cannabis-mediated visual effects in humans, particularly an
increase in glare recovery at low contrast [15], a reduction
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in Vernier and Snellen acuities [16, 17], improvement in
night vision [18, 19], blurred vision [20], changes in color
discrimination, and an increase in photosensitivity [21]. Most
of the latter (psychophysical) effects may have a retinal
component, which might be due to neurochemical changes
induced by the retinal endocannabinoid system. Indeed,
many physiological effects of cannabinoids were reported
for every retinal cell type in bovines, guinea pigs, rodents,
and fishes (for review see [10, 22]). In the bovine retina,
the activation of CB1R increases monoamine oxidase [23].
In the guinea pig retina, stimulation of CB1R results in the
inhibition of dopamine release [24], and in the rat retina,
the activation of cannabinoid receptors modulates [35S]
GTP𝛾 S-binding and voltage-dependent membrane currents
in photoreceptors, bipolar cells, and ganglion cells [3, 25–28].
In addition, cannabinoid agonists increase the cone response
to light offset in the goldfish retina [29].
The electroretinogram (ERG) is a useful tool for assessing
retinal function by measuring the electrical responses of all
populations of retinal cells, mainly photoreceptors (cones
and rods), bipolar cells, amacrine cells, and Mu¨ller cells
[30–32]. The ERG waves include two main components:
the negative amplitude (a-wave) and the positive one (b-
wave). Traditionally, the a-wave reflects the response of rods
and cones to light [33, 34]. The generation of the b-wave,
the second major component of the ERG, is attributed to
the inner retina, mainly the depolarization of bipolar and
Mu¨ller cells [30–32, 35–39]. Specific stimuli and recording
environments are selected to isolate the components of the
ERG and target particular populations of retinal cells. For
instance, rod function is assessed in dark-adapted eyes, under
scotopic conditions, while cone responses are better assessed
with high intensity flashes, under photopic conditions [38].
In this study, we investigated the changes in normal retinal
function as measured by electroretinography in adult vervet
monkeys after blockade of CB1R or CB2R by their antagonists
AM251 and AM630, respectively.
2. Material and Methods
2.1. Choice of Species. Vervet monkeys are becoming the
preferred animal model used in biomedical research sec-
ond only to the rhesus macaque [41]. Vervets are very
similar in physiology and behavior to macaques, and they
are more accessible and disease-free with less health and
safety risks. Vervet monkeys have a foveal binocular vision
with a high cone density that decreases with eccentricity,
trichromatic color vision, and a six-layered dorsal lateral
geniculate nucleus [42, 43]. Recently, we have standardized
a noninvasive, painless ERGmethod for vervet monkeys [40]
that showed highly comparable recordings to macaques [44]
and humans [45].
2.2. Subjects. Sixteen vervet monkeys (Chlorocebus sabaeus)
were tested in this study. Six of those monkeys were injected
with AM251, and another six were injected with AM630. An
additional 4 monkeys were injected with the vehicle (DMSO)
used to dilute of our antagonists in order to provide control
values. The animals were fed with primate chow (Harlan
Teklad High Protein Monkey Diet; Harlan Teklad, Madi-
son, WI, USA) and fresh local fruits, with water available
ad libitum. All experiments were performed according to
the guidelines of the Canadian Council on Animal Care
(CCAC) and the Association for Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic and Vision Research.The experimental protocol
was also reviewed and approved by the local Animal Care
and Use Committee (University of Montreal, protocol # 14-
007) and the Institutional Review Board of the Behavioral
Science Foundation. None of the animals were sacrificed for
this study.
2.3. Animal Preparation for ERG Recordings. All procedures
were in accordance with the standard protocol of elec-
troretinography in vervet monkeys [40]. Briefly, all animals
received an intramuscular injection of ketamine (10mg/kg;
Troy Laboratories, Glendenning, New South Wales, Aus-
tralia) and xylazine (1mg/kg; Lloyd Laboratories, Shenan-
doah, IA, USA) to maintain an adequate level of sedation
that prevents the animals from moving and blinking. This
drug mixture has no effect on the ERG recordings [46].
With 1% tropicamide (Mydriacyl) and 2.5% phenylephrine
hydrochloride (Mydfrin) (Alcon Laboratories, Fort Worth,
TX, USA), the pupils were fully dilated (approximately 9mm
in diameter), with the accommodation paralyzed.The cornea
was anesthetized with 0.5% proparacaine hydrochloride
(Alcaine; Alcon Laboratories, Fort Worth, TX, USA). To
prevent corneal drying, the eyes were moisturized frequently
with 2.5% methylcellulose (Gonak; Akorn, Inc., Buffalo
Grove, IL, USA). Body temperature was maintained between
36.5∘C and 38∘Cwith a heating pad. After a recording session
that lasted about 2 hours, the animals were sent back to their
prior natural settings after a recovery period in isolation.
2.4. Intravitreal Injection. The CB1R antagonist AM251 was
purchased from Cayman Chemicals (Ann Arbor, MI, USA).
The CB2R antagonist AM630 was purchased from Tocris
(Tocris Bioscience, Ellisville, MO, USA). Both antagonists
were diluted in DMSO under sterile conditions. Assuming
no leakage, the final concentration was 1.5% v/v for DMSO,
0.01mg/𝜇L for AM251, and 0.003mg/𝜇L for AM630. To
factor out any effects of the vehicle (DMSO), we subtracted
the ERG recordings of the DMSO-injected animals from the
ERG recordings of the drug injected animals. In this way, the
effects that we report are only those above and beyond effects
of the vehicle. After inspection and examination of the eyes,
the cornea was cleaned with 5% povidone-iodine solution for
45 seconds. A drop of the topical anesthetic, proparacaine,
was then applied over the injection site.The conjunctival and
corneal surfaces were furthermoistenedwithmethylcellulose
(Moisture Eyes, Bausch & Lomb Canada, Vaughan, ON,
Canada).The corneawas protectedwith sterile coatingswhile
placing the Barraquer eye speculum (1.75 inches, 10mmwide
small blades). A total of 50 𝜇L of drug solution was injected
2mm posterior to the corneal limbus into the vitreous
cavity. Upon removal of the needle, the injection site was
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Figure 1: A schematic procedure illustrating a typical ERG recording session for testing ERG changes following an intravitreal injection in
vervet monkeys (modified from [40]). LA, light adaptation; Phot, photopic.
compressed for about one minute using a sterile cotton swab
to avoid reflux. The back of the eye was inspected using an
ophthalmoscope before and after the intravitreal injection to
verify the integrity of the retina. No substantial differences
were observed in intraocular pressure before and after the
intravitreal administration. As a follow-up, the animals’ eyes
were checked every day for seven days following injection,
and a topical antibiotic ointment was administered (Tobrex,
0.3% tobramycin ophthalmic ointment, Alcon Canada, Mis-
sissauga, Canada).
2.5. Visual Stimulation. Full-field stimulation was produced
by a Ganzfeld light source (UTAS E-3000 electrophysiology
equipment; LKCTechnologies, Inc., Gaithersburg,MD,USA)
that was placed in front of the animal’s face. The ERGs
were evoked by <5ms white flashes delivered in full-field
conditions. Xenon flash luminance of 2.5 to 800 cd⋅s⋅m−2
(0 dB to 20 dB in LKC units) was used for photopic record-
ings and LED flash luminance of 2.5 × 10−5 to 6 cd⋅s⋅m−2
(−40 dB to 4 dB in LKC units) for scotopic recordings.
For light-adapted ERGs a steady background-adapting field
(30 cd⋅m−2) was presented inside the Ganzfeld to saturate
the rod system. Dark adaptation lasted approximately 20
minutes. Interstimulus intervals of at least 20 seconds were
used at high intensities in the dark-adapted eyes. Flash
intensities and background luminancewere calibrated using a
research radiometer (IL1700 Photometer, International Light
Inc., Newburyport,MA,USA)with a SED033 detector placed
at 36 cm from the source.
2.6. ERG Recording. All ERG procedures followed the ISCEV
guidelines and the recently published standardized ERG pro-
tocol of vervet monkeys [40]. ERG responses were recorded
separately between corneal contact lens electrodes (Jet elec-
trodes, Diagnosys LLC, Lowell, MA, USA) lying across the
center of the cornea of each eye. The jet electrodes were
equippedwith four small posts on the convex surface in order
to keep the eyelids open. Reference and ground gold disc
electrodes (model F-E5GH; Grass Technologies, Astro-Med,
Inc., West Warwick, RI, USA) were, respectively, placed to
the external canthi and forehead with adhesive paste (Ten20
conductive EEG paste, Kappa Medical, Prescott, AZ, USA).
For the analysis of the waveforms, the a-wave amplitude was
measured from the baseline to the trough of the a-wave.
The amplitude of the b-wave was measured from the trough
of the a-wave to the peak of the b-wave. The peak latency
was defined from the onset of the flash to the trough or
peak. Baselines and postinjection photopic amplitudes and
latencies were calculated as averages to minimize the noise
inherent in the ERG signals and improve power, allowing
for robust parametric statistical analysis. Since there was
only one baseline recording of the injected eye, the baseline
value was calculated from an average across both eyes (when
available) since ERGs do not vary considerably across eyes
[47]. For the postinjection values, we had several recordings
from the injected eye (one every 10 minutes for 40 minutes).
Visual inspection revealed the peak effect to be present at
both the 30 and 40minutes of postinjection recordings.These
were therefore averaged to obtain postinjection values for
each intensity flash. Retinal response diagrams were drawn
using Adobe Illustrator and processed in Adobe InDesign
(Adobe Systems Canada, Ottawa, ON, Canada, software
version CS5). The recording protocol for assessing the effect
of the drugs is summarized in Figure 1.
2.7. Statistical Analysis. The absolute trough (a-wave) and
peak (b-wave) of the ERG curves were obtained at each light
intensity value. When the ERG curve for low light intensities
(<−2 log cd⋅s⋅m−2) did not return to baseline 350ms after the
stimulus, the amplitudes of the a- and b-wave were corrected
to account for the baseline shift. When no a-wave, or no
wave at all, was detected, an amplitude of 0 was given and
the latency was left blank for that specific stimulus intensity.
Outliers (±2.5 SD)were removed (<2%overall). Postinjection
amplitudes and latencies were expressed as percent of change
from preinjection amplitudes (postinjection minus prein-
jection, divided by preinjection). The delta change percent-
ages of injecting AM251 and AM630 were then subtracted
from the delta change percent for the control injection, the
vehicle DMSO. Thus, positive normalized effects indicate
an increase as a result of injecting the drug, greater than
the change that results from injecting the vehicle alone. To
assess the statistical significance of the observed increase,
we analyzed the amplitudes of the a- and b-waves using
General Estimating Equations (GEE) with flash intensity as
within subject factor, because each monkey was repeatedly
measured (at each flash intensity). These main effects, and
their interaction, were used to estimate the normalized effects
of retinal injection of AM251 and AM630 on retinal function.
Significant effects were followed up, when appropriate, with
pairwise comparisons, significant values indicated with stars
in the relevant figures.
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Figure 2: Raw photopic ERGs in the different drug injection groups. Representative ERGs recorded after intravitreal injection of DMSO
(a), AM251 (b), or AM630 (c). ERG recordings of each treated animal were established by presenting progressively brighter flashes (top to
bottom). Horizontal calibration, 20ms; vertical calibration, 75 𝜇V.
3. Results
3.1. Retinal Function in Photopic Conditions. Retinal function
was evaluated using electroretinography in light-adapted
conditions following injection of the vehicle DMSO, the
CB1R antagonist AM251, or the CB2R antagonist AM630
(Figure 2).
3.2. Photopic b-Wave. Our results show that the amplitudes of
the b-wave after injection maintained a normal photopic hill
shape indicating that the functional integrity of the retina was
not impaired (Figure 3(a)). GEE analysis revealed a signifi-
cant main effect of flash intensity (𝑝 < .001), and a significant
interaction between the flash intensity and injection group
(𝑝 = .001). The interaction was followed up with pairwise
comparisons. AM251 was not significantly different from
DMSOat any of the flash intensities (Figure 3(b)). In contrast,
AM630 caused a significant increase in amplitude, relative
to the control injection, across several flash intensities, from
0.6 to 1.6 log cd⋅s⋅m−2 (0.6: 55% increase in amplitude relative
to the control, 𝑝 = .041; 0.9: 53% increase, 𝑝 = .038;
1.4: 63% increase, 𝑝 = .003; 1.6: 60% increase, 𝑝 = .011;
significant effects indicated with ∗ in Figure 3(c)). The main
effect of AM251 is, on average, a 6% increase, which is not
significantly different from the vehicle alone, represented by
zero on the 𝑦-axis of Figures 3(b)–3(d) (𝑝 = .713). The
main effect of AM630, averaged across all flash intensities, is a
nonsignificant, but trending, 34% increase in responsiveness
of the retina compared to the vehicle alone (𝑝 = .067,
Figure 3(d)). Latencies were also analyzed with the same
GEE model and the interaction (𝑝 < .05) was followed
up as above. Pairwise comparisons revealed no significant
differences, between the drugs and the vehicle, at any of the
flash intensities (not shown).
3.3. Photopic a-Wave. Our results show that, after injection,
the amplitude of the a-wave followed the normal curve
(Figure 4(a)). The effect of the drugs was, however, quite
different from the vehicle. GEE analysis revealed a significant
main effect of flash intensity (𝑝 < .001), and a significant
interaction between the flash intensity and drug group (𝑝 <
.001). This interaction indicates that the effect of the drugs
was not the same across all flash intensities. The interaction
was followed up with pairwise comparisons. AM251 caused
a significantly higher amplitude than DMSO at the highest
flash intensities of 2.4 and 2.9 log cd⋅s⋅m−2 (2.4: 36% increase
in amplitude relative to the vehicle, 𝑝 = .040; 2.9: 32%
increase, 𝑝 = .038; significant effects indicated with ∗ in
Figure 4(b)). For its part, AM630 caused a significant increase
in amplitude, relative to the control injection, across a larger
set of flash intensities, from 0.9 to 2.9 log cd⋅s⋅m−2 ((0.9:
30% increase, 𝑝 < .001; 1.4: 38% increase, 𝑝 = .002; 1.6:
32% increase, 𝑝 = .001; 2.4: 39% increase, 𝑝 = .015; 2.9:
35% increase, 𝑝 = .006), significant effects indicated with
∗ in Figure 4(c)). AM251 caused an increase in the a-wave
amplitude only at the highest flash intensities, while AM630
increases the a-wave amplitude across a wider set of flash
intensities. The main effect of AM251 is, on average, a 12%
increase, which is not significant relative to the vehicle alone
(𝑝 = .428). Conversely, the main effect of AM630, averaged
across all flash intensities, is a nonsignificant but trending
26% increase in the responsiveness of the retina compared
to the vehicle alone (𝑝 = .080, Figure 4(d)). Latencies were
also analyzed with the same GEE model and the interaction
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Figure 3: Photopic b-wave amplitudes. (a) Amplitudes of photopic ERG b-waves plotted as a function of flash intensities. (b) Scatter plot for
normalized b-wave amplitude as a function of flash intensity in AM251-injected monkeys. Grey points indicate raw values; red data points
with error bars indicate the mean and standard error of the mean. (c) Scatter plot and linear regression for normalized b-wave amplitude as
a function of flash intensity in AM630-injected monkeys. Grey points indicate raw values; blue data points with error bars indicate the mean
and standard error of the mean. (d) Main effect of average amplitudes across intensities in AM251 (red) or AM630 (blue) groups. ∗𝑝 < .05.
(𝑝 < .05) was followed up as above. Pairwise comparisons
at each intensity value revealed no significant differences
between the drugs and the vehicle (not shown).
3.4. Retinal Function in Scotopic Condition. To assess the
effect of the cannabinoid receptor antagonists in scotopic
conditions, ERG responses of the dark-adapted retina were
also registered after administration of DMSO, AM251, or
AM630. The ERG tracings maintained their normal shape
following injection. However, the amplitudes of the b-wave
were increased for both treatment groups, while the drugs did
not reliably alter the pattern of the a-waves (Figure 5).
3.5. Scotopic b-Wave. After injection, the amplitude of the
scotopic b-waves had the normal shape: increasing ampli-
tudes for increasing flash intensities (Figure 6(a)). The effect
of the drugs was, however, quite different from the vehicle.
GEE analysis revealed a significant main effect of injection
group (𝑝 < .001). There was no main effect of flash intensity
(𝑝 = .842) nor was there an interaction of group with flash
intensity (𝑝 = .953). Due to a lack of interaction, pairwise
comparisons at each flash intensity were not justified, but
mean and standard errors are plotted in Figure 6(b) (AM251)
and Figure 6(c) (AM630). Following up on the main effect of
drug, pairwise comparisons between groups revealed signif-
icantly higher amplitudes following the injection of AM251
compared to the vehicle alone (20% increase, 𝑝 < .001)
and a similar increase in amplitude following injection of
AM630 (18% increase,𝑝 = .002) (Figure 6(d)).The difference
between these two drugs was not significant (𝑝 = .596).
Latencies had the same pattern of effect as the amplitudes.
Both pharmacological agents led to a significant increase in
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Figure 4: Photopic a-wave amplitudes. (a) Amplitudes of photopic ERG a-waves plotted as a function of flash intensities. (b) Scatter plot for
normalized a-wave amplitude as a function of flash intensity in AM251-injected monkeys. Grey points indicate raw values; red data points
with error bars indicate the mean and standard error of the mean. (c) Scatter plot and linear regression for normalized a-wave amplitude as
a function of flash intensity in AM630-injected monkeys. Grey points indicate raw values; blue data points with error bars indicate the mean
and standard error of the mean. (d) Main effect of average amplitudes across intensities in AM251 (red) or AM630 (blue) groups. ∗𝑝 < .05.
the latency relative to the vehicle (AM251: 8%, 𝑝 = .036;
AM630: 12%, 𝑝 = .001). No interactions were present (not
shown).
3.6. Scotopic a-Wave. After injection, the amplitude of the
scotopic a-wave had the normal shape: increasing amplitudes
for increasing flash intensities, beginning at −1 log cd⋅s⋅m−2
(Figure 7(a)). Therefore, the statistical analysis for the sco-
topic a-wave only involved the values obtained from the
flashes at −1 to 1.4 log cd⋅s⋅m−2. GEE analysis revealed a
significant main effect of flash intensity (𝑝 = .001) and a
significant interaction between the intensity of the flash and
the drug injected (𝑝 < .001). The interaction was followed
up with pairwise comparisons, between the drugs and the
vehicle alone, at each flash intensity value. This revealed no
significant differences, between the drugs and the vehicle,
at any of the intensities (Figures 7(b) and 7(c)). Thus, while
the two agonists cause varied effects at the different flash
intensities, the effects of each drug relative to the vehicle
alone, at a given flash intensity, were not reliable enough to be
significant.The overall effect of AM251 and AM630, averaged
across the flash intensities, was not significantly different
from the vehicle alone (Figure 7(d)). Latencies were also
analyzed with the same GEE model and the interaction (𝑝 <
.05) was followed up as above. Pairwise comparisons revealed
one significant difference at flash intensity 0.6; following
injection of AM251, the latency to peak was 21% slower
compared to the injection of the vehicle alone (𝑝 = .011, not
shown).
Neural Plasticity 7
DMSO
0.0
0.4
0.6
1.4
−3.6
−3.4
−3.2
−2.8
−2.6
−2.2
−2.0
−1.0
−0.6
20ms
150𝜇V
Fl
as
h 
in
te
ns
ity
 (l
og
 cd
·s·
m
−
2
)
(a)
Fl
as
h 
in
te
ns
ity
 (l
og
 cd
·s·
m
−
2
)
AM251
0.0
0.4
0.6
1.4
−3.6
−3.4
−3.2
−2.8
−2.6
−2.2
−2.0
−1.0
−0.6
20ms
150𝜇V
(b)
Fl
as
h 
in
te
ns
ity
 (l
og
 cd
·s·
m
−
2
)
AM630
0.0
0.4
0.6
1.4
−3.6
−3.4
−3.2
−2.8
−2.6
−2.2
−2.0
−1.0
−0.6
20ms
150𝜇V
(c)
Figure 5: Raw scotopic ERGs in the different drug injection groups. Representative ERGs recorded after intravitreal injection of DMSO
(a), AM251 (b), or AM630 (c). ERG recordings of each treated animal were established by presenting progressively brighter flashes (top to
bottom). Horizontal calibration, 20ms; vertical calibration, 75 𝜇V.
4. Discussion
The purpose of this study was to determine the role of
cannabinoid receptors CB1 and CB2 in the normal monkey
retina. The abundance of CB1R and CB2R expression in
the retina already pointed to an important role of these
receptors in normal vision. We analyzed changes in photopic
and scotopic ERG responses after blocking these receptors
with their respective antagonists. The experimental design
used DMSO as the control, rather than preinjection values,
to control for any effects of the vehicle. We demonstrated
that, in photopic conditions, only the blockade of CB2R
increased the amplitude of the b-wave, above the standard
flash intensity value, while blocking CB1R or CB2R increased
the amplitude of the a-wave, at high flash intensity values.
In scotopic conditions, however, blockade of either CB1R or
CB2R increased only the amplitude of the b-wave irrespective
of flash intensity.
4.1. Photopic Condition. The amplitude of the main compo-
nent of the ERG, the photopic b-wave, represents primarily
the activation of depolarization ON-bipolar cells measured
as a positive retinal potential on the corneal surface [36, 48–
50]. In addition, the b-wave is attributed to the interaction of
ON-bipolar cells and Mu¨ller glial cells [36, 37]. In the vervet
monkey, CB1R is expressed mainly in cones and in the other
retinal components, while CB2R is exclusively present in the
glial Mu¨ller cells, leading to a complementary relationship
between neurons and glia regarding endocannabinoid action
[6]. The light-induced potassium increase in the outer and
inner plexiform layers’ cells, which are depolarized by light
stimulation, modifies the Mu¨ller cell membrane potential
thereby generating electrical responses [51]. Mu¨ller cells, via
KCNJ10 (KIR4.1) channels and potassium siphoning of the
excess potassium ions into the vitreous [52, 53], control the
light-mediated potassium increase in retinal extracellular
space [54]. The depolarization of the Mu¨ller cells contributes
to the ERG b-wave through the buffering of potassium chan-
nels [35, 55, 56]. Thus, the blockade of potassium channels
should result in a decrease of the ERG b-wave [37]. Our
results revealed a significant increase of the photopic b-wave
amplitude following the blockade of CB2R, which supports
our previously proposed model [6]. CB2R coupled to Gi/o
decreases cAMP levels and the PKA activity [57]. PKA is
a positive modulator of potassium channels and therefore,
the blockade of CB2R via an increase of PKA activity will
increase the activity of K+ channels in Mu¨ller cells, and thus
an increased photopic b-wave amplitude (Figure 8). It may
also be possible that AM630 affected the OFF cone pathway
that originates from the dendritic contacts of bipolar cells
with cones, which could partially explain the increase of
the photopic b-wave amplitude only at the middle intensity
flash values [58]. Another potential interpretation is that
since CB2R is not expressed on cones [6], AM630 may
have modulated other non-CB2 receptors located on cone
photoreceptors.
The a-wave measured under photopic conditions repre-
sents cone function. Stimulation of cones by light inhibits
retinal dark currents through phototransduction signals that
take place in the cone outer segments as seen in the a-wave
of the ERG. The early portion of the a-wave represents the
activity of the cone photoreceptors [59, 60], while the later
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Figure 6: Scotopic b-wave amplitudes. (a) Amplitudes of scotopic ERG b-waves plotted as a function of flash intensities. (b) Scatter plot for
normalized b-wave amplitude as a function of flash intensity in AM251-injected monkeys. Grey points indicate raw values; red data points
with error bars indicate the mean and standard error of the mean. (c) Scatter plot and linear regression for normalized b-wave amplitude as
a function of flash intensity in AM630-injected monkeys. Grey points indicate raw values; blue data points with error bars indicate the mean
and standard error of the mean. (d) Main effect of average amplitudes across intensities in AM251 (red) or AM630 (blue) groups. ∗𝑝 < .05.
portion reflects the contribution of hyperpolarizing bipolar
cells, proximal amacrine cells, and ganglion cells [61–63].
Stimulation of conesmay activate the CB1R in its pedicles [5],
which in turn leads to the inhibition of glutamate release in
the synaptic cleft. Blocking CB1R will therefore result in the
increase in glutamate release. This increase mimics the effect
of a bright light that contributes to larger amplitude of the
photopic a-wave. Blocking CB2R on the other hand has an
even larger effect on the amplitude of the a-wave, which can
be explained by a similar mechanism that involves additional
potassium buffering by Mu¨ller cells [6] (Figure 8(a)). Other
receptors that contribute to the photopic b-wave may also
explain howAM630 could affect the photopic a-wave. Indeed,
the increase of the photopic b-wave might cause a large
change in the a-wave (a result of cone modulation), which
would be independent of the action of Mu¨ller cells.
4.2. Scotopic Condition. Thea-wavemeasured under scotopic
conditions represents rod function. In the dark-adapted
retina, blockade of either CB1R or CB2R had no significant
effect on the scotopic a-wave.This null effect can be explained
by the small quantity of CB1R expressed in the rod spherules
in primates [3, 5]. In contrast, the large quantity of putative
cannabinoid receptor (GPR55), found exclusively in rods
[64], has a significant effect on the scotopic ERG [65]. It has
been reported that AM251 could be also a GPR55 agonist
[66]. Thus, we cannot rule out that the increase of the
scotopic b-wave amplitude following the injection of AM251
Neural Plasticity 9
Flash intensity (log cd·s·m−2)
0
DMSO AM251AM630
−300
−250
−200
−150
−100
−50
a-
w
av
e a
m
pl
itu
de
 (𝜇
V
)
−4 −3 −2 −1 0 1 2
(a)
N
or
m
al
iz
ed
 a-
w
av
e a
m
pl
itu
de
 (%
)
0
50
100
150
−1
−100
−50
0 1 2
Flash intensity (log cd·s·m−2)
(b)
Flash intensity (log cd·s·m−2)
0 2
N
or
m
al
iz
ed
 a-
w
av
e a
m
pl
itu
de
 (%
)
0
50
100
150
−100
−1
−50
1
(c)
AM251 AM630
N
or
m
al
iz
ed
 a-
w
av
e a
m
pl
itu
de
 
av
er
ag
ed
 ac
ro
ss
 in
te
ns
iti
es
 (%
)
0
10
20
30
40
50
−10
(d)
Figure 7: Scotopic a-wave amplitudes. (a) Amplitudes of scotopic ERG a-waves plotted as a function of flash intensities. (b) Scatter plot for
normalized a-wave amplitude as a function of flash intensity in AM251-injected monkeys. Grey points indicate raw values; red data points
with error bars indicate the mean and standard error of the mean. (c) Scatter plot for normalized a-wave amplitude as a function of flash
intensity in AM630-injected monkeys. Grey points indicate raw values; blue data points with error bars indicate the mean and standard error
of the mean. (d) Main effect of average amplitudes across intensities in AM251 (red) or AM630 (blue) groups. Error bars represent standard
error or the mean.
might be due to GPR55 activity. However, CB1R is found in
large quantities in rod bipolar cells [5] and, in conjunction
with CB2R in Mu¨ller cells [6], likely contributes to the
large increase of the scotopic b-wave amplitude. Differential
effects between CB1R and CB2R might be explained by the
nature of the ion channels involved. The potassium buffering
role of Mu¨ller cells leads to the increase of the scotopic
b-wave following CB2R blockade. The calcium increase in
postsynaptic rod bipolar cells results from CB1R blockade
(see Figure 8(b)). Since CB1R agonists induce a reduction in
the amplitude of calcium channel currents in retinal bipolar
cells [3], it is not surprising, as shown here, that the CB1R
antagonist AM251 had the opposite effect: mainly, an increase
in rod bipolar cells activity.
5. Conclusion
These findings might be helpful for the development of new
pharmacological targets for the treatment of retinal intoxi-
cation [67, 68] and diseases [69]. These retinal pathologies
are generally associated with a decrease in the amplitude of
the electroretinographic waves. We show here that pharma-
cological agents that block the retinal cannabinoid receptors
can induce an increase in the amplitude of the ERG response
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Figure 8: Schematic illustration of the proposed mechanisms underlying the actions of AM251 and AM630 in the monkey retina, as revealed
by electroretinography under photopic (a) and scotopic (b) conditions. (See Discussion for details.)
profiles. Manipulating the endocannabinoid system might
therefore serve as a therapy to restore normal vision and
protect the retina.
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